手机验证
/
MNNG/HOS; MNNG-HOS; HOS-MNNG; HOS/MNNG; MNNGHOS; MNNG-HOS (Cl#5); MNNG/HOS Clone F-5; TE85; Te85; TE-85; HOS TE85; HOS (TE85); HOS(TE85); HOS (TE85, Clone F5); MNNG-HOS (TE 85, clone F-5); HOS-Te85; TE 85.T; TE 85 ClF-5; TE-85 clone 5
/
充足
/
/
/
/
/
/
人骨肉瘤细胞
人
/
上皮细胞样
/
/
复苏发货或干冰冷冻发货
/
贴壁
1 x 10^6 cells/vial/T25
细胞名称:MNNG/HOS Cl #5人骨肉瘤细胞(STR鉴定正确)
产品货号:C1201
培养条件:MEM+10%FBS(货号:M0301)
生长特性:贴壁
细胞形态:上皮样
产品规格:1 x 10^6 cells/vial/T25
产品货号 | 细胞名称 | 中文名称 | 生长特性 | 细胞形态 | 产品规格 |
C1151 | 143B | 人骨肉瘤细胞 | 混合 | 贴壁 | 1 x 10^6 cells/vial/T25 |
C1089 | RPMI-8226 | 人多发性骨肉瘤细胞 | 淋巴母细胞 | 悬浮 | 1 x 10^6 cells/vial/T25 |
C1132 | U-2 OS | 人骨肉瘤细胞 | 上皮样 | 贴壁 | 1 x 10^6 cells/vial/T25 |
C1136 | Saos-2 | 人成骨肉瘤细胞 | 上皮样 | 贴壁 | 1 x 10^6 cells/vial/T25 |
C1140 | SW 1353 | 人软骨肉瘤细胞 | 成纤维细胞 | 贴壁 | 1 x 10^6 cells/vial/T25 |
C1187 | SJSA-1 | 人骨肉瘤细胞 | 成纤维细胞 | 贴壁 | 1 x 10^6 cells/vial/T25 |
C1014 | MG-63 | 人骨肉瘤细胞 | 成纤维细胞样 | 贴壁 | 1 x 10^6 cells/vial/T25 |
C1215 | KHOS-240S | 人骨肉瘤细胞 | 上皮样 | 贴壁 | 1 x 10^6 cells/vial/T25 |
用户须知:
1、关于货期:除复苏细胞外,承诺货期1周内到(节假日顺延),大多数产品1-3天内发货。细胞产品因需要复苏后进行1-2代传代调整后等待细胞长满,期间进行微生物检测,货期1、2周左右。
2、关于订购:为了保证您的权益,下单前务必联系我司客户服务热线(021-55150076)。
安全性:
所有肿瘤和病毒转染的细胞均视为有潜在的生物危害性,必须在二级生物安全台内操作,并请注意防护。
公司简介:
WheLab 是一家位于上海的高新技术公司,专注于细胞培养和分子生物学资源开发,服务于各大科研院校、医院和医药企业。 公司拥有先进的分子实验室、细胞培养间、液氮罐,收藏了1000+ 种细胞系,来源于ATCC细胞,DSMZ细胞,JCRB细胞,RIKEN细胞,ScienCell细胞等机构。同时包含自主研发建系的各类示踪细胞、耐药株、基因敲除细胞等。实验室可配制基础实验所需的常规试剂,实验室管理规范,细胞株均有STR鉴定和支原体检测,质量保证! 我们拥有国内、美国海归等丰富经验与专业技术的精英团队,秉承“专业、诚信、可靠”为公司宗旨,以合理的价格,完善的服务,提供可靠的产品,为广大客户提供完整的生物细胞技术解决方案。
如果您需要进一步的信息和服务,欢迎联系我们。
联系人:童小姐
电话:15921090068(微信同号)
:2306932016
:021-55150076
官网:https://whelab.com
公司邮箱:info@whelab.com
技术邮箱:tech@whelab.com
地址:上海宝山区呼兰西路129号8号楼4层
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
PubMed=265298; DOI=10.1002/ijc.2910190411
Rhim J.S., Putman D.L., Arnstein P., Huebner R.J., McAllister R.M.
Characterization of human cells transformed in vitro by N-methyl-N'-nitro-N-nitrosoguanidine.
Int. J. Cancer 19:505-510(1977)
PubMed=833871; DOI=10.1093/jnci/58.2.209
Fogh J., Wright W.C., Loveless J.D.
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977)
PubMed=6254071; DOI=10.1073/pnas.77.9.5258
Todaro G.J., Fryling C.M., De Larco J.E.
Transforming growth factors produced by certain human tumor cells: polypeptides that interact with epidermal growth factor receptors.
Proc. Natl. Acad. Sci. U.S.A. 77:5258-5262(1980)
PubMed=22282976; DOI=10.1093/carcin/1.1.21
Day R.S. III, Ziolkowski C.H.J., Scudiero D.A., Meyer S.A., Mattern M.R.
Human tumor cell strains defective in the repair of alkylation damage.
Carcinogenesis 1:21-32(1980)
PubMed=6269117; DOI=10.3181/00379727-167-41221
Rhim J.S.
Characterization of sarcoma-positive, leukemia-negative (S+L-) human cells induced by the feline leukemia virus pseudotype of Moloney sarcoma virus.
Proc. Soc. Exp. Biol. Med. 167:597-606(1981)
PubMed=6575958; DOI=10.1007/BF02619599
Tsang K.-Y., Fudenberg H.H., Sun D.C., Pai G.S., Bishop L.R., Sager S.
Cultivation of human osteosarcoma cell lines in serum-free hormone supplemented medium.
In Vitro 19:515-521(1983)
PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)
PubMed=2823272; DOI=10.1073/pnas.84.21.7716
Masuda H., Miller C., Koeffler H.P., Battifora H.A., Cline M.J.
Rearrangement of the p53 gene in human osteogenic sarcomas.
Proc. Natl. Acad. Sci. U.S.A. 84:7716-7719(1987)
PubMed=2978869
Ehrhart J.-C., Duthu A., Ullrich S., Appella E., May P.
Specific interaction between a subset of the p53 protein family and heat shock proteins hsp72/hsc73 in a human osteosarcoma cell line.
Oncogene 3:595-603(1988)
PubMed=3335022
Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.
Cancer Res. 48:589-601(1988)
PubMed=1385192; DOI=10.1016/0531-5565(92)90007-m
Fleming T.P., Matsui T., Aaronson S.A.
Platelet-derived growth factor (PDGF) receptor activation in cell transformation and human malignancy.
Exp. Gerontol. 27:523-532(1992)
PubMed=7873286; DOI=10.1016/8756-3282(94)90305-0
Clover J., Gowen M.
Are MG-63 and HOS TE85 human osteosarcoma cell lines representative models of the osteoblastic phenotype?
Bone 15:585-591(1994)
PubMed=12645653; DOI=10.1016/S0165-4608(02)00685-4
Ozaki T., Neumann T., Wai D.H., Schaefer K.-L., van Valen F., Lindner N., Scheel C., Bocker W., Winkelmann W., Dockhorn-Dworniczak B., Horst J., Poremba C.
Chromosomal alterations in osteosarcoma cell lines revealed by comparative genomic hybridization and multicolor karyotyping.
Cancer Genet. Cytogenet. 140:145-152(2003)
PubMed=19787792; DOI=10.1002/gcc.20717
Ottaviano L., Schaefer K.-L., Gajewski M., Huckenbeck W., Baldus S., Rogel U., Mackintosh C., de Alava E., Myklebost O., Kresse S.H., Meza-Zepeda L.A., Serra M., Cleton-Jansen A.-M., Hogendoorn P.C.W., Buerger H., Aigner T., Gabbert H.E., Poremba C.
Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort.
Genes Chromosomes Cancer 49:40-51(2010)
PubMed=21519327; DOI=10.1038/labinvest.2011.72
Mohseny A.B., Machado I., Cai Y., Schaefer K.-L., Serra M., Hogendoorn P.C.W., Llombart-Bosch A., Cleton-Jansen A.-M.
Functional characterization of osteosarcoma cell lines provides representative models to study the human disease.
Lab. Invest. 91:1195-1205(2011)
PubMed=24136885; DOI=10.1002/pbc.24801
Guma S.R., Lee D.A., Yu L., Gordon N., Hughes D., Stewart J., Wang W.L., Kleinerman E.S.
Natural killer cell therapy and aerosol interleukin-2 for the treatment of osteosarcoma lung metastasis.
Pediatr. Blood Cancer 61:618-626(2014)
PubMed=26320182; DOI=10.18632/oncotarget.5177
Ren L., Mendoza A., Zhu J., Briggs J.W., Halsey C., Hong E.S., Burkett S.S., Morrow J.J., Lizardo M.M., Osborne T., Li S.Q., Luu H.-H., Meltzer P.S., Khanna C.
Characterization of the metastatic phenotype of a panel of established osteosarcoma cells.
Oncotarget 6:29469-29481(2015)
PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)
PubMed=29334376; DOI=10.1038/nm.4475
Morrow J.J., Bayles I., Funnell A.P.W., Miller T.E., Saiakhova A., Lizardo M.M., Bartels C.F., Kapteijn M.Y., Hung S., Mendoza A., Dhillon G., Chee D.R., Myers J.T., Allen F., Gambarotti M., Righi A., DiFeo A., Rubin B.P., Huang A.Y., Meltzer P.S., Helman L.J., Picci P., Versteeg H.H., Stamatoyannopoulos J.A., Khanna C., Scacheri P.C.
Positively selected enhancer elements endow osteosarcoma cells with metastatic competence.
Nat. Med. 24:176-185(2018)
需要更多技术资料 索取更多技术资料
细胞售后说明.pdf 附 (下载 0 次)